Riaan Receives First Human Gene Therapy for Cockayne Syndrome After Family Raises $4 Million
Updated
Updated · HuffPost · Aug 15
Riaan Receives First Human Gene Therapy for Cockayne Syndrome After Family Raises $4 Million
3 articles · Updated · HuffPost · Aug 15
Summary
April 21, 2026 marked the first known human dosing of a gene therapy for Cockayne syndrome, when 6-year-old Riaan underwent brain surgery in New York and was reported to have come through the procedure well.
The treatment delivers a healthy copy of the CSA gene into his brain to try to restore protein production and slow a fatal DNA-repair disorder that had left him with an expected lifespan of about 5 years.
Riaan’s family said they spent years building the program themselves, raising $4 million, working with scientists and clinicians, and securing FDA clearance after filing an Investigational New Drug application.
More than 3 months after treatment, Riaan remains clinically stable and his family says they have seen early encouraging changes, though any benefit could take months or years to assess and may not last.
The group says enough drug was manufactured for multiple children and plans to re-engage with the FDA to seek approval for treating other Cockayne syndrome patients while raising funds for clinical costs.
Will this unprecedented brain surgery to rewrite a six-year-old's DNA pave the way for curing other ultra-rare diseases?
What happens when the only chance to save a child requires risking their life in an experimental, first-in-human trial?
How did a desperate mother bypass traditional pharma to create a custom brain therapy for her dying son?
Breaking Barriers: The World’s First Gene Therapy for Cockayne Syndrome—Riaan’s Journey, Parent-Led Innovation, and the $4 Million Path to Clinical Trial
Overview
After their son Riaan was diagnosed with Cockayne syndrome, Jo Kaur and Richard Digeorge founded the Riaan Research Initiative (RRI) to develop a treatment for this ultra-rare disease. Facing little interest from pharmaceutical companies, they raised nearly $4 million through public advocacy and coordinated a complex, multi-institutional drug development pipeline. This led to the first-ever administration of an experimental AAV9 gene therapy to Riaan in April 2026. His recovery is being closely monitored for signs of improvement. The RRI’s journey highlights both the promise of parent-led drug development and the challenges of equity and access in ultra-rare disease therapies.